Skip to main content

Table 1 Inclusion/exclusion criteria

From: A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin®for treatment of osteoarthritis of the knee

Criteria

Details

Inclusion

Patients must understand risks and benefits of the protocol and be able to give informed consent

 

Male and female patients aged 40 to 80 years

 

Females of child-bearing potential must agree to use an approved form of birth control and to have a negative pregnancy test result.

 

Unilateral or bilateral osteoarthritis of the knee for more than 3 months

 

Visual analogue scale score during the most painful knee movement between 40 and 70 mm after 7 days of withdrawal of usual medication

 

Lequesne's Functional Index score greater than 7 points after 7 days of withdrawal of usual medication

 

Ability to walk

 

Availability for the duration of the entire study period

Exclusion

History of underlying inflammatory arthropathy or severe rheumatoid arthritis

 

Hyperuricaemia (>440 μmol/l) and/or past history of gout

 

Recent injury in the area affected by osteoarthritis of the knee (past 4 months) and expectation of surgery in the next 4 months

 

Intra-articular corticosteroid injections within the preceding 3 months

 

Hypersensitivity to nonsteroidal anti-inflammatory drugs, abnormal liver or kidney function tests, history of peptic ulceration and upper gastrointestinal haemorrhage, congestive heart failure, hypertension, hyperkalaemia

 

Major abnormal findings on complete blood count, history of coagulopathies, haematological or neurological disorders

 

High alcohol intake (>2 standard drinks per day)

 

Pregnant, breastfeeding, or planning to become pregnant during the study

 

Use of concomitant prohibited medication other than ibuprofen

 

Obesity (body mass index > 30 kg/m2)